News and Announcements
Kazia Therapeutics features in multiple leading Australian publications
- Published April 19, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Highlights
- Kazia Therapeutics (ASX: KZA) has recently appeared across multiple leading Australian financial publications and guest speaker at a Brisbane investor event.
- Media mentions include small-cap publication, Stockhead, nabtrade and investment newsletter, the Switzer Report
- Kazia CEO James Garner also presented at the Wholesale Investor Emergence event providing an update on Kazia’s lead programs and trials.
Kazia Therapeutics (ASX: KZA) has recently appeared across multiple leading Australian financial publications as well as presenting at the recent Wholesale Investor Emergence event.
CEO James Garner featured in small-cap publication, Stockhead, in regards to a bid to form an integrated approach for new options for cancer patients following Bill Shorten’s $2.3 billion cancer funding pledge.
Kazia has also been featured by financial journalist James Dunn as a leading ASX cancer stock to watch in both nabtrade and investment newsletter, the Switzer Report
Kazia CEO James Garner also presented at the Wholesale Investor Emergence event in Brisbane, detailing Kazia’s expected multiple data read-outs from its international human trials during calendar 2019 and an update on Kazia’s lead program, GDC-0084 to target glioblastoma.
About Kazia Therapeutics Limited (ASX: KZA)
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) is developing cancer treatments for areas which there is a high unmet medical need. Our lead program, GDC-0084, a drug to treat glioblastoma multiforme, the most aggressive brain cancer, has completed phase 1 human trials with strong safety and early efficacy signals. It is currently being prepared for phase 2 human trials.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
